Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS - Koji Sasaki, Elias Jabbour, Guillermo Montalban-Bravo, Faezeh Darbaniyan, Kim-Anh Do, Caleb Class, Nicholas J. Short, Rashmi Kanagal-Shamana, Tapan Kadia, Gautam Borthakur, Naveen Pemmaraju, Jorge Cortes, Farhad Ravandi, Yesid Alvarado, Kelly Chien - Dissemin

Language
Login

Published in

NEJM Evidence, 10(1), 2022

DOI: 10.1056/evidoa2200034

Links

Massachusetts Medical Society

Tools

Export citation

Search in Google Scholar

Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS

Journal article published in 2022 by Koji Sasaki, Elias Jabbour, Guillermo Montalban-Bravo, Faezeh Darbaniyan, Kim-Anh Do, Caleb Class, Nicholas J. Short, Rashmi Kanagal-Shamana, Tapan Kadia, Gautam Borthakur, Naveen Pemmaraju, Jorge Cortes, Farhad Ravandi, Yesid Alvarado, Kelly Chien and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Orange circle

Published version: archiving restricted

Upload

Policy details

Data provided by

SHERPA/RoMEO